TTC18 Inhibitors
TTC18 inhibitors encompass a variety of chemical compounds that interact with specific signaling pathways to reduce the functional activity of TTC18. For instance, LY294002 and Wortmannin are both phosphatidylinositol 3-kinase (PI3K) inhibitors that, by hampering the PI3K/Akt pathway, could lead to decreased TTC18 activity if TTC18 is modulated by PI3K signaling. Similarly, PD98059 and U0126, as MEK inhibitors, obstruct the MAPK/ERK pathway, which could suppress TTC18 activity if it is regulated by this signaling cascade. The p38 MAPK inhibitor SB203580, and the JNK inhibitor SP600125, function by disrupting their respective MAPK pathways, potentially attenuating TTC18 functionality if it is connected to these signaling routes. PP2, a Src family kinase inhibitor, may also indirectly lead to diminished TTC18 activity by inhibiting Src kinase activity and its downstream signals that might govern TTC18 regulation.
Further illustrating the diversity of TTC18 inhibitors, Rapamycin's inhibition of mTOR signaling can result in decreased TTC18 activity if TTC18 is part of the mTOR pathway. Targeted kinase inhibitors like Gefitinib, which inhibits EGFR, and Sorafenib, which targets RAF kinase along with VEGFR and PDGFR, could also reduce TTC18 activity if it is activated by these kinases' signals. Similarly, Imatinib and Dasatinib, by inhibiting BCR-ABL, PDGFR, c-Kit, and Src family kinases, have the potentialto decrease TTC18 activity by targeting the underlying kinases that might influence TTC18's function. These inhibitors collectively demonstrate the intricate web of signaling pathways that can be manipulated to achieve a reduction in TTC18 activity, each working through distinct molecular interactions and processes to exert their inhibitory effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Phosphatidylinositol 3-kinase (PI3K) inhibitor that impedes the PI3K/Akt pathway. Since TTC18's activity may be modulated by PI3K signaling due to its role in cellular processes, inhibition of this pathway can lead to reduced functional activity of TTC18. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that obstructs the MAPK/ERK pathway. As TTC18 could be influenced by ERK signaling, blocking this pathway with PD98059 can suppress the functional activity of TTC18. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that disrupts the p38 MAPK signaling cascade. By impeding this pathway, the inhibitor may attenuate the functional activity of TTC18 if it is associated with p38 MAPK-dependent processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that inhibits the JNK signaling pathway. This inhibition could decrease TTC18 activity if TTC18 is regulated by JNK-mediated signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2 which prevents the activation of MAPK/ERK pathway. If TTC18 functions downstream of or is regulated by this pathway, U0126 can lead to a reduction in TTC18 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that can suppress the PI3K/Akt pathway, potentially leading to a decrease in TTC18 activity if it is PI3K/Akt pathway-dependent. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor that can inhibit Src kinase activity and potentially downstream signaling that may regulate TTC18, resulting in a decrease in TTC18 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can suppress mTORC1 and mTORC2 complexes. If TTC18 is involved in mTOR signaling, inhibition by rapamycin could lead to a decrease in TTC18 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor. If TTC18 is activated by EGFR signaling, inhibition by gefitinib could decrease TTC18 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor that also inhibits VEGFR and PDGFR. By targeting these kinases, sorafenib could reduce TTC18 activity if TTC18 is regulated by any of these pathways. | ||||||